Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.

× No keyword cloud information.

33 in total

1. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies.

Authors: P L Dahia; R C Aguiar; J Alberta; J B Kum; S Caron; H Sill; D J Marsh; J Ritz; A Freedman; C Stiles; C Eng
Journal: Hum Mol Genet Date: 1999-02 Impact factor: 6.150

2. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.

Authors: Y E Whang; X Wu; H Suzuki; R E Reiter; C Tran; R L Vessella; J W Said; W B Isaacs; C L Sawyers
Journal: Proc Natl Acad Sci U S A Date: 1998-04-28 Impact factor: 11.205

3. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.

Authors: D M Li; H Sun
Journal: Cancer Res Date: 1997-06-01 Impact factor: 12.701

4. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.

Authors: K Podsypanina; R T Lee; C Politis; I Hennessy; A Crane; J Puc; M Neshat; H Wang; L Yang; J Gibbons; P Frost; V Dreisbach; J Blenis; Z Gaciong; P Fisher; C Sawyers; L Hedrick-Ellenson; R Parsons
Journal: Proc Natl Acad Sci U S A Date: 2001-08-14 Impact factor: 11.205

5. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Authors: M S Neshat; I K Mellinghoff; C Tran; B Stiles; G Thomas; R Petersen; P Frost; J J Gibbons; H Wu; C L Sawyers
Journal: Proc Natl Acad Sci U S A Date: 2001-08-14 Impact factor: 11.205

6. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors: P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal: Nat Genet Date: 1997-04 Impact factor: 38.330

Review 7. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.

Authors: G B Mills; Y Lu; X Fang; H Wang; A Eder; M Mao; R Swaby; K W Cheng; D Stokoe; K Siminovitch; R Jaffe; J Gray
Journal: Semin Oncol Date: 2001-10 Impact factor: 4.929

8. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors: J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal: Science Date: 1997-03-28 Impact factor: 47.728

9. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.

Authors: A Bellacosa; D de Feo; A K Godwin; D W Bell; J Q Cheng; D A Altomare; M Wan; L Dubeau; G Scambia; V Masciullo; G Ferrandina; P Benedetti Panici; S Mancuso; G Neri; J R Testa
Journal: Int J Cancer Date: 1995-08-22 Impact factor: 7.396

10. PIK3CA is implicated as an oncogene in ovarian cancer.

Authors: L Shayesteh; Y Lu; W L Kuo; R Baldocchi; T Godfrey; C Collins; D Pinkel; B Powell; G B Mills; J W Gray
Journal: Nat Genet Date: 1999-01 Impact factor: 38.330

23 in total

Review 1. Crosstalk of oncogenic and prostanoid signaling pathways.

Authors: Rolf Müller
Journal: J Cancer Res Clin Oncol Date: 2004-06-15 Impact factor: 4.553

2. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.

Authors: David Schiff; Kurt A Jaeckle; S Keith Anderson; Evanthia Galanis; Caterina Giannini; Jan C Buckner; Phillip Stella; Patrick J Flynn; Bradley J Erickson; John F Schwerkoske; Vesna Kaluza; Erin Twohy; Janet Dancey; John Wright; Jann N Sarkaria
Journal: Cancer Date: 2018-01-03 Impact factor: 6.860

3. Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.

Authors: Roberta Malaguarnera; Kuen-Yuan Chen; Tae-Yong Kim; Jose M Dominguez; Francesca Voza; Bin Ouyang; Sushil K Vundavalli; Jeffrey A Knauf; James A Fagin
Journal: J Clin Endocrinol Metab Date: 2014-07-16 Impact factor: 5.958

4. New molecular targeted therapies for advanced non-small-cell lung cancer.

Authors: Míriam Méndez; Ana Custodio; Mariano Provencio
Journal: J Thorac Dis Date: 2011-03 Impact factor: 2.895

5. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance.

Authors: Deyin Xing; Sandra Orsulic
Journal: Proc Natl Acad Sci U S A Date: 2005-04-28 Impact factor: 11.205

6. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells.

Authors: Ravi D Rao; Ann C Mladek; Jeffrey D Lamont; Jennie M Goble; Charles Erlichman; C David James; Jann N Sarkaria
Journal: Neoplasia Date: 2005-10 Impact factor: 5.715

7. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

Authors: Christine C Hudson; Mei Liu; Gary G Chiang; Diane M Otterness; Dawn C Loomis; Fiona Kaper; Amato J Giaccia; Robert T Abraham
Journal: Mol Cell Biol Date: 2002-10 Impact factor: 4.272

8. Growth, invasion, metastasis, differentiation, angiogenesis and apoptosis of gastric cancer regulated by expression of PTEN encoding products.

Authors: Hua-Chuan Zheng; Yi-Ling Li; Jin-Min Sun; Xue-Fei Yang; Xiao-Han Li; Wei-Guo Jiang; Yin-Chang Zhang; Yan Xin
Journal: World J Gastroenterol Date: 2003-08 Impact factor: 5.742

9. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake.

Authors: Aimee L Edinger; Craig B Thompson
Journal: Mol Biol Cell Date: 2002-07 Impact factor: 4.138

Review 10. Hereditary breast cancer: new genetic developments, new therapeutic avenues.

Authors: Philippe M Campeau; William D Foulkes; Marc D Tischkowitz
Journal: Hum Genet Date: 2008-06-25 Impact factor: 4.132